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Abstract 34 
 35 
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple 36 
sclerosis (RRMS).  We aim to review the published literature on ocular manifestations of fingolimod 37 
therapy and their possible underlying mechanisms.  38 
The therapeutic effects of fingolimod are mediated via sphingosine receptors, which are found 39 
ubiquitously in various organs including lymphoid cells, central nervous system, cardiac myocytes and 40 
smooth muscle cells.  Fingolimod associated macular oedema (FAME) is the most common ocular 41 
side effect but retinal haemorrhages and retinal vein occlusion can occur. The visual consequences 42 
appear to be mild and, in cases of FAME, resolution is often attained with discontinuation of therapy.  43 
However, in cases of retinal vein occlusion, discontinuation of fingolimod alone may not be sufficient 44 
and intra-vitreal therapy may be required. We also propose a pragmatic service pathway for 45 
monitoring patients on fingolimod therapy, which includes stratifying them by risk and visual acuity. 46 
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Introduction 64 
 65 
Fingolimod is the first orally administered agent to be licensed by the Food and Drug Administration 66 
(FDA), and also approved by the National Institute for Health and Care Excellence (NICE), for use in 67 
patients with highly active relapsing remitting multiple sclerosis (RRMS) after recent clinical trials 68 
demonstrated its efficacy in reducing the frequency of relapses and disability progression on long 69 
term follow–up of patients with multiple sclerosis when compared with placebo (1,2).  These 70 
therapeutic effects in multiple sclerosis therapy are thought to be due to the action of fingolimod on 71 
preventing the egression of lymphocytes from lymphoid tissue into the circulation thereby sparing the 72 
central nervous system from attack by myelin-reactive lymphocytes (3, 4).  In vivo, fingolimod exerts 73 
this immunomodulating effect through a novel mechanism by binding sphingosine-1-phosphate (S1P) 74 
receptors on lymphocytes.  Although S1P receptors are found with the highest density in leucocytes 75 
and lymphoid tissue, they are also widely expressed in many cell types in other organs systems 76 
including the heart, brain, liver, stomach and probably also in the retina.  This ubiquitous nature of the 77 
target receptor for fingolimod accounts for the wide range of adverse effects including hypertension, 78 
heart block, bradycardia and macular oedema. 79 
 80 
In the original pivotal FREEDOMS study all seven patients with macular oedema had been 81 
randomized to, and received, fingolimod (1).  Since its launch in 2010, numerous reports of a variety 82 
of adverse events associated with fingolimod therapy have been published.  This has led to the 83 
recommendation that patients should have cardiac and ophthalmic evaluation prior to commencing 84 
fingolimod and at every 3-4 months during therapy (5). 85 
 86 
Given the recent anecdotal reports of Fingolimod Associated Macular oEdema (FAME) and other 87 
retinal complications, coupled with the paucity of data on the putative pathogenic mechanisms 88 
responsible for the effect of fingolimod in the eye, we have reviewed the relevant published literature 89 
with the aim of summarising the current concepts on the mode of action of fingolimod, collating the 90 
available body of clinical experience on diagnosis, treatment and outcomes of ophthalmic 91 
complications presumed to be associated with fingolimod therapy.  This article should provide 92 
ophthalmologists with an initial current reference base for the management of patients on fingolimod 93 
therapy in clinical practice and should also provide some insight into the possible pathogenic 94 
mechanisms responsible, which could serve to focus our thoughts on the development of more 95 
specifically targeted therapy for these novel retinal problems.  With this information, we then go on to 96 
suggest a pragmatic care pathway for the ophthalmic monitoring of patients on fingolimod therapy.  97 
 98 
Fingolimod’s mode of action and its cardiovascular side effects 99 
In vivo, fingolimod is phosphorylated to fingolimod-phosphate and becomes structurally similar to a 100 
sphingolipid called sphingosine-1-phosphate (S1P), an extracellular mediator, preventing it from 101 
binding normally to the five types of S1P receptors (S1PR1-5).  At the cellular level, it leads to 102 
internalisation and eventual degradation of these cell surface receptors and abnormal cellular function 103 
and communication (4,6).  S1P receptors are found on lymphocytes and other organs and whilst in 104 
MS it has the desired therapeutic effect of reducing the up-regulation of lymphocytes and their 105 
migration from lymphoid tissue into the circulation and the central nervous system, the destruction of 106 
S1P receptors in other organs is responsible for its cardiovascular and probably also retinal side 107 
effects. 108 
The location of S1P receptors on cardiac myocytes and smooth muscle cells is probably responsible 109 
for the adverse cardiovascular effects of fingolimod, which include bradycardia, atrioventricular nodal 110 
block and systemic hypertension.  Bradycardia occurs in 0.6% of patients treated with fingolimod.  It is 111 
typically observed 4-5 hours after the first dose, with a mean maximum heart rate reduction of 8bpm.  112 
S1PR1 activation with fingolimod activates G-protein coupled inwardly-rectifying potassium channels 113 
(GIRKs) on myocytes.  This leads to an efflux of potassium, thereby hyperpolarising the cell 114 
membrane and temporarily reducing excitability.  This effect is transient but leads to internalisation of 115 
S1PR1.  This same mechanism is responsible for Mobitz type 1 second-degree AV nodal block 116 
observed in 0.2% of those patients treated with fingolimod (6,7).  An increase in blood pressure is 117 
observed in patients treated with fingolimod.  This increase is, on average, +2mmHg systolic and 118 
+1mmHg diastolic.  This effect is believed to be via the presence of S1PR1, S1PR2 and S1PR3 119 
receptors in arterial smooth muscle cells.  Activation of S1PR1 in arterial smooth muscle cells causes 120 
increased nitric oxide production (therefore vasodilation) as well as an intracellular increase in 121 
calcium.  This rise in calcium causes an increase in smooth muscle contraction; therefore these 122 
opposing effects initially offset one another.  However, once S1PR1 internalises, binding shifts to 123 
S1PR2 and S1PR3 that are also found on arterial smooth muscle cells, thus smooth muscle 124 
contraction is the over-riding force.  This effect on blood pressure is prolonged longer than first-dose 125 
related bradycardia and AV nodal block, with a peak at 6 months after which it stabilises (6). 126 
 127 
Fingolimod and the eye 128 
In the retina the effects of fingolimod on the actions of the sphingolipid, sphingosine-1-phosphate and 129 
its S1P receptors are less well understood.  Sphingolipids are the third most abundant lipid in the 130 
retina (8).  It is well recognised that sphingolipid metabolism plays important roles in retinal cell death 131 
and survival. This balance is referred to as the “sphingolipid rheostat.” Ceramide (Cer) is the key 132 
metabolite for sphingolipid production.  There are two major pathways for Cer production - de novo 133 
synthesis for higher-order sphingolipids and the recycling/degradation of higher order sphingolipids.  134 
Aberrant sphingolipid metabolism is known to cause various metabolic storage diseases such as Tay-135 
Sachs, Fabry’s disease and Niemann-Pick disease (9).  Although fingolimod can potentially affect 136 
sphingolipid metabolism globally in the whole retina by inhibiting Cer enzymes, thereby reducing the 137 
formation of de novo Cer (9) it seems that this is unlikely to be pathogenic mechanism behind the 138 
causation of macular oedema that have been reported in the recent literature as all the cases have 139 
reported very localised distribution of oedema to the macular area only and not globally across the 140 
whole retina (10-21). 141 
There are a number of ocular conditions that have been linked to fingolimod.  The most common is 142 
fingolimod associated macular oedema (FAME), the only ocular condition to have been mentioned in 143 
the original FREEDOMS and TRANSFORMS trials as well as in the drug marketing literature. 144 
However since 2010, when fingolimod has been used outside of these clinical trials, several other 145 
ocular side effects have been reported including retinal haemorrhages and retinal vein occlusion (22-146 
24). 147 
 148 
Pathophysiology of FAME 149 
The proposed pathophysiological mechanism of FAME is based upon the interaction between 150 
fingolimod and S1PR1 present on endothelial cells in retinal vessels.  S1PR1 signalling is responsible 151 
for maintaining cell-to-cell and cell-to-matrix adhesion complexes.  The use of fingolimod is thought to 152 
down regulate this receptor, thus leading to down regulation of adhesion complexes and subsequent 153 
increased retinal vascular permeability resulting in oedema (25, 26).  154 
 155 
Incidence of FAME 156 
Macula oedema has been a well-documented side effect of fingolimod since it was originally 157 
evaluated as an anti-rejection agent for renal transplantation (27, 28).  FAME was therefore monitored 158 
for and reported in the initial clinical trials investigating the efficacy of fingolimod for RRMS.  The 159 
FREEDOMS study was a phase III multicentre, 24-month, double blind randomised study comparing 160 
0.5mg (n=425) and 1.25mg (n=429) fingolimod daily treatment with placebo (n=418) in patients with 161 
RRMS (1).  None of the 425 patients receiving 0.5mg fingolimod developed macular oedema.  Seven 162 
out of 429 (1.6%) patients receiving 1.25mg fingolimod developed macular oedema and three of 163 
these were reported as serious.  In 5 out of those 7 patients, macular oedema occurred within 3 164 
months of starting treatment.  In 6 out of those 7 patients the macular oedema had resolved within 6 165 
months of discontinuing therapy.  The past ophthalmic history was not reported in any of these cases 166 
in the FREEDOMS study. 167 
The TRANSFORMS study was a phase III multicentre, 12 month, double blind randomised study 168 
comparing fingolimod 0.5mg (n=429) and 1.25mg (n=420) to IFN-1a intramuscularly (n=431) in 169 
patients with RRMS (29).  Two out of 429 patients receiving 0.5mg treatment (0.5%) and 4 out of 420 170 
(1%) patients receiving 1.25mg treatment developed macular oedema.  Three of those 6 patients 171 
were visually asymptomatic and macular oedema was diagnosed only on macular examination.  Five 172 
out of those 6 patients developed macular oedema within 4 months of treatment initiation.  In 4 out of 173 
those 6 patients, macular oedema had resolved within 3 months of treatment discontinuation.  In the 174 
remaining 2 patients one was unchanged 1 month after treatment discontinuation and one had 175 
reduction of macula oedema 8 months after treatment discontinuation.  It is not known whether these 176 
patients had ocular co-morbidities prior to entering the FREEDOMS and TRANSFORMS studies.  The 177 
FREEDOMS II study (30) was a separate phase III clinical trial to the original FREEDOMS study and 178 
the TRANSFORMS study.  It was conducted as the FDA had stipulated the need for additional 179 
monitoring, such as Holter monitoring, which was not performed in the original FREEDOMS and 180 
TRANSFORMS studies.  FREEDOMS II was a phase III multicentre 24-month double-blind 181 
randomised control trial comparing fingolimod 0.5mg vs. fingolimod 1.25mg vs. placebo in the 182 
treatment for RRMS.  Macular oedema was reported in 4 out of 370 (1%) in the 1.25mg group, 3 out 183 
of 358 (0.8%) in 0.5mg group and, interestingly, 2 out of 355 (0.6%) in the placebo group. All those 184 
cases of FAME in this study resolved with the discontinuation of therapy except one in the 1.25mg 185 
group and one in the placebo group.  To our knowledge, none of the patients with resolution of 186 
macular oedema after fingolimod discontinuation were re-challenged by recommencing fingolimod in 187 
the prospective studies. 188 
Both the FREEDOMS and TRANSFORMS studies had parallel extension studies to assess the long-189 
term effects of fingolimod therapy.  These studies found no further increased risk of FAME over a 190 
period of up to 4.5 years (2, 31).  In a retrospective study by Ontaneda et al a similar incidence 191 
(3/317, 0.9%) of macular oedema at 3 months after therapy initiation was reported (32). 192 
Regarding the onset of FAME Zarbin et al, using pooled analysis of data from the phase II core and 193 
extension study with the phase III core and extension studies of FREEDOMS and TRANSFORMS, 194 
reported that FAME developed within 3-4 months of commencing fingolimod in 68% of affected cases 195 
(33). 196 
From the analysis of the 15 patients (24 eyes) we found from published case reports (Table 1), the 197 
time of onset of FAME after commencement of fingolimod was within 6 months for all but two cases.  198 
In these two cases, both had been on fingolimod for an extended period (1 year in one case, 2 years 199 
in the other) and macular oedema only occurred after cataract surgery, suggesting that these may not 200 
be directly related to FAME per se.  The majority of cases (12 out of 15) developed FAME within 4 201 
months of initiation of therapy and 7 out of 15 occurred within 1 month.  This was in keeping with the 202 
experience from the FREEDOMS and TRANSFORMS clinical trials. In summary, FAME can occur 203 
within the first six months of commencing fingolimod therapy. The incidence appears to be dose-204 
dependent, occurring in 0.4% of patients treated with 0.5mg, and in 1% of those treated with 1.25mg 205 
(10-21).  206 
 207 
Symptoms of FAME 208 
Although the cases identified in the FREEDOMS and TRANSFORMS trials were not reported in 209 
sufficient detail to review their symptomatology, the case reports were a very useful source of this 210 
information.  Of the 15 patients (24 eyes) with FAME reported as case reports in the literature (Table 211 
1), the majority were symptomatic; the most common presenting complaint being painless blurred 212 
vision.  One patient had metamorphopsia and another patient was asymptomatic but actually had 213 
reduced vision of 6/18.  Presenting vision was mildly reduced (20/30 or better) in 8 of 24 eyes and 214 
moderately reduced (20/30 – 20/80) in the remainder (16 of 24 eyes).  The worst visual acuity 215 
reported in an eye with FAME was 6/24 or, approximately, 20/80. 216 
 217 
Diagnosis of FAME 218 
In all of the 15 cases of retinal problems thought to be attributed to fingolimod therapy, all of them had 219 
abnormal signs on OCT scanning or fluorescein angiography of either macular thickening, foveal or 220 
perifoveal cysts, subretinal fluid, venous tortuosity or dye leakage.  These findings are easily visible 221 
on biomicrospcopy and OCT scanning.  Fluorescein angiography can be used to rule out other 222 
causes of macular oedema such as posterior uveitis or retinal vein occlusion or diabetic retinopathy.  223 
In making the diagnosis of FAME, it is important to be aware that neuronal loss and retinal thinning 224 
can result in the presence of degenerative microcysts in about 4-5% of patients with MS, typically 225 
seen in the inner nuclear layer on OCT scanning.  Although these cysts have been termed microcystic 226 
macular oedema secondary to multiple sclerosis, they are probably not due to transudation or 227 
exudation as they are not known to be associated with reduced visual acuity or dye leakage on 228 
fluorescein angiography and are more often associated with reduced macular volume and overall 229 
retinal thinning particularly in patients with long standing or severe MS (34, 35).   230 
 231 
Management of FAME 232 
Although Zarbin et al reported that 84% of patients had macular oedema resolution after fingolimod 233 
cessation in the All Studies group, there are numerous reports of cases in which discontinuation did 234 
not lead to resolution and needed topical prednisolone and ketorolac (18). There are also reports on 235 
cases in which fingolimod was not discontinued and this led to persistence of MO (11), and variable 236 
resolution with topical nepafenac and difluprednate (17), topical ketorolac and dexamethasone (13), 237 
oral acetazolamide (19), sub-tenon triamcinolone (20) and intravitreal triamcinolone (21).  From these 238 
reports, it appears that the current steps for managing FAME is to firstly to confirm the diagnosis with 239 
OCT scan and fluorescein angiography to rule out other causes of MO and then discontinue 240 
fingolimod if possible.  Persistent MO on early follow-up can then be treated with topical steroidal or 241 
non-steroidal agents initially before introducing subtenon or intravitreal triamcinolone.  There is no 242 
evidence base available at present for the use of intravitreal ozurdex, intravitreal anti-VEGF or oral 243 
corticosteroids in the management of FAME. 244 
 245 
FAME and its association with uveitis 246 
Zarbin et al suggested a higher risk of developing FAME in patients with a history of uveitis than those 247 
without (33).  Using pooled analysis of data from the phase II core and extension study with the phase 248 
III core and extension studies of FREEDOMS and TRANSFORMS (N=2615), a total of 19 cases had 249 
reported macular oedema.  The prevalence of patients with a history of uveitis in this dataset was 1% 250 
(26 out of 2615), but interestingly amongst those who developed macular oedema the prevalence of a 251 
history of uveitis was 26% (5 out of 19).  Thus the incidence of macular oedema amongst those with a 252 
history of uveitis was 19% (5/26) compared with the overall incidence of macular oedema in the 253 
dataset being 0.7% (19 out of 2615).  All 5 patients with uveitis who developed macular oedema were 254 
taking 1.25mg fingolimod.  It is difficult to comment on the link between FAME and uveitis from the 255 
case reports detailed in Table 1, as there is no control for comparison but it can be noted that out of 256 
the 14 case reports containing sufficient detail on past ocular history, there were only two patients 257 
with a history of uveitis prior to commencing fingolimod. The findings from the analysis of these 258 
anecdotal case reports therefore support the suggestion by Zarbin et al that although patients without 259 
any history of uveitis can develop FAME, those with a past history of uveitis probably have an 260 
increased risk of developing FAME. 261 
 262 
FAME and its association with diabetes 263 
Patients with diabetes mellitus were excluded from the FREEDOMS and TRANSFORMS clinical 264 
trials.  The clinical trials assessing the use of fingolimod as an anti-rejection agent in renal transplant 265 
patients was reported by Salvadori et al and Tedesco-Silva et al.  Both these clinical trials evaluated 266 
higher dose fingolimod (5mg and 2.5mg) in association with cyclosporine and both reported higher 267 
rates of macular oedema (Salvadori et al: 2.2% at 5mg dose, 1.3% at 2.5mg dose) (27), (Tedesco-268 
Silva et al: 3.4% at 5mg dose and 1.7% at 2.5mg) (28).  Tedesco-Silva and Salvadori did not exclude 269 
patients with diabetes in the sample population.  However, as doses used were up to 10 times higher 270 
than the licensed dose today, it is difficult to state whether this increase in rate of FAME is due to the 271 
higher dosage or the fact that diabetic patients were included in the sample.  In addition, as diabetic 272 
patients were not excluded from the study, it is difficult to conclude whether the macular oedema was 273 
caused by fingolimod or related to diabetic maculopathy.  Furthermore, in the case reports we 274 
reviewed, only 2 out of 14 patients had diabetes and one with no diabetic retinopathy, there is 275 
insufficient evidence to suggest that patients with diabetes or diabetic retinopathy without 276 
maculopathy are at an increased risk of developing FAME with fingolimod. 277 
It is reasonable; however, to suspect that diabetic patients are more likely to be prone to macular 278 
oedema than non-diabetic patients, due to an already compromised blood-retinal barrier, thus 279 
fingolimod must be used with caution in this cohort of patients 280 
 281 
Fingolimod and Retinal Haemorrhages 282 
To date, there have been two cases of retinal haemorrhage in patients treated with fingolimod 283 
therapy.  Bhatti et al report a 54-year-old female, with no history of diabetes mellitus or hypertension, 284 
who had been treated with 0.5mg of fingolimod for 11 months for RRMS.  She presented with a grey 285 
opaque spot in her visual field and LVA of 20/80.  A unilateral, dense retinal haemorrhage involving 286 
the fovea with an adjacent hard exudate and macular thickening were confirmed on OCT in her left 287 
eye.  FFA of the affected eye revealed fluorescein blockage due to blood and lipid exudates and 288 
hyperfluorescence adjacent due to areas of blockage, but without overt angiographic signs of retinal 289 
vein occlusion.  Fingolimod was promptly discontinued and one month later the macular haemorrhage 290 
had completed resolved.  By three months, visual acuity had recovered to baseline of 20/30 and OCT 291 
was normal (22).  Ueda and Saida reported a case of a 31-year-old male with RRMS and pre-existing 292 
poor visual acuity (OD 20/600, OS 20/400), who developed both macular oedema and retinal 293 
haemorrhages in all four quadrants unilaterally in his left eye one month after commencing fingolimod 294 
therapy.  Treatment was discontinued but due to persisting FAME 13 weeks after cessation of therapy 295 
topical betamethasone 0.1% was commenced.  The macular oedema resolved 4 weeks after this 296 
addition of topical steroid (17 weeks after cessation of fingolimod), and the haemorrhages resolved 11 297 
weeks after the addition of topical steroid (24 weeks after cessation of fingolimod) (23). The 298 
mechanism by which fingolimod may cause retinal haemorrhages has not yet been fully elucidated, 299 
though it may also be linked with the S1PR1 mechanism of FAME, rendering retinal blood vessels 300 
increasingly permeable (25, 26). 301 
 302 
Fingolimod and its association with retinal vein occlusion 303 
As retinal vein occlusion (RVO) is a common condition, it is uncertain whether a link exists between 304 
RVO and fingolimod therapy.  To date, only one previous report of branch retinal vein occlusion has 305 
been published in the literature.  Gallego-Pinazo et al. described a case of a 47-year-old female 306 
patient with a 9-year history of MS.  She had been treated with fingolimod for 6 years prior to 307 
developing unilateral sudden visual reduction in her left eye to 20/40 due to a superotemporal BRVO 308 
associated with macular oedema and central foveal thickness of 396µm.  FFA typically revealed an 309 
area of delayed venous filling and blockage of fluorescence by the intraretinal haemorrhages. 310 
Fingolimod was discontinued and the patient was treated with one intravitreal ranibizumab injection.  311 
The patient had neither cardiovascular risk factors, nor any coagulation abnormality suggestive of an 312 
alternative cause for RVO.  Three weeks later, visual acuity had improved to 20/20 in the patient’s left 313 
eye and there was almost complete resolution of retinal oedema (24). It is uncertain whether 314 
fingolimod has a thrombogenic effect in veins but Nealon et al describe a case of a patient who 315 
developed a thrombus in a developmental venous angioma two months after commencing fingolimod 316 
therapy (36).  Similar to the patient described by Gallego-Pinazo, this patient also did not have any 317 
recognised cardiovascular risk factors or coagulation abnormality.  Thus, the authors concluded that 318 
fingolimod could be thrombogenic.  Schwarz et al reported a patient who developed critical arterial 319 
vasospasm of the left arm within 7 days of commencing fingolimod therapy.  Considering the half-life 320 
of fingolimod is 9 days and the maximum vasospasm occurred at 13 days post-discontinuation, they 321 
argued that this chronological sequence is suggestive of a causal relationship between fingolimod and 322 
vasospasm (37).  If vasospasm were to occur at the point of an AV crossing, a retinal vein occlusion 323 
would ensue. Lastly, as fingolimod causes a rise in blood pressure, one could argue that this could 324 
have facilitated retinal vein occlusion. However, due to the transient and also rather modest (+2mmHg 325 
systolic) rise in blood pressure, this mechanism seems unlikely (6, 7).  326 
 327 
Ophthalmic monitoring in patients on fingolimod therapy 328 
The time of onset of FAME after commencement of fingolimod was within 6 months for all but two 329 
cases.  Both of these cases had been on fingolimod for an extended period (1 year in one case, 2 330 
years in the other) and CMO developed in both these cases only after cataract surgery, a known 331 
trigger for developing CMO.  The majority of cases (12/15) developed FAME within 4 months of 332 
initiation of therapy, keeping in line with the original FREEDOMS and TRANSFORMS clinical trials. 333 
Therefore, screening patients on fingolimod after 3-4 months as per NICE guidelines seems 334 
appropriate.  Moosavi et al performed a retrospective study to assess the adherence to these NICE 335 
guidelines and to measure the impact of delivery of these guidelines on clinical service.  In a 9-month 336 
period, 38 referrals for fingolimod screening were made, contributing to a significant 9% of new 337 
referrals.  Only 1 patient had FAME, who had in fact developed blurred vision soon after fingolimod 338 
initiation and was seen in the eye clinic at 5 weeks post commencement where OCT confirmed 339 
FAME; shorter than the 3-4 month recommendation.  Moosavi et al concluded that reviewing 340 
fingolimod patients at 3-4 months is a huge burden to eye services for a rare side effect.  They 341 
recommend that near and distance acuity is measured by the physician prescribing fingolimod, and 342 
referrals to an ophthalmologist should only be made if there is a reduction in acuity or a change in 343 
visual symptoms (38).  As with Moosavi’s study, we also found from most of the case reports 344 
published that the majority of patients had symptoms of visual blurring.  This is in contrast to the 345 
original FREEDOMS and TRANSFORMS trials that reported fingolimod ocular effects to be 346 
asymptomatic.  This perception from the FREEDOMS and TRANSFORMS trials that fingolimod 347 
effects on the eye is often asymptomatic may be the reason for the stipulation by NICE for routine 348 
ophthalmic screening at 3-4 months in all patients commencing fingolimod therapy.  Given the low 349 
incidence of ocular effects and the higher likelihood that such effects are associated with visual 350 
symptoms, we would like to propose a pragmatic pathway for implementing the NICE guidelines on 351 
screening.  Figure 1 shows the proposed pathway based on previous ocular history and a simple 352 
visual acuity measurement prior to discontinuation of fingolimod or referral to hospital ophthalmology 353 
departments.  If there is a past history of uveitis or diabetic retinopathy, patients could be screened 354 
before commencement of fingolimod to rule out active maculopathy, as the addition of fingolimod may 355 
exacerbate pre existing disease. In those patients with a history of ocular comorbidities but no active 356 
disease, review in eye clinic within the most likely time window for the development of FAME (3-4 357 
months) is suggested.  However in those with no significant ophthalmic history, we propose that a 358 
baseline visual acuity measurement are performed by the physician prescribing fingolimod followed 359 
by a further visual acuity test and OCT 3-4 months later in a virtual eye clinic.  In the unlikely event 360 
that a patient with FAME is asymptomatic, there will still be an opportunity for such a patient to be 361 
detected in this screening pathway at the second contact in the virtual eye clinic. As the risk of FAME 362 
is low after 4 months, screening beyond this time is probably unnecessary. However, as patients on 363 
fingolimod therapy, regardless of duration, who undergo intraocular surgery are at an increased risk of 364 
FAME, it is suggested that this cohort of patients have a routine OCT at the pre and postoperative 365 
check.  366 
 367 
Conclusion 368 
In summary, there is a significant association of macular oedema (FAME) and other retinal vascular 369 
problems in patients who are on treatment with fingolimod for MS.  Fortunately the visual 370 
consequences appear to be mild and often resolve on discontinuation of fingolimod therapy.  The 371 
pathophysiologic mechanism responsible for FAME is thought to be due to an increased permeability 372 
of the retinal vessels due to the effect of fingolimod on retinal sphingolipid receptors.  However, in 373 
rarer cases where there is retinal vein occlusion, discontinuation of fingolimod alone may not lead to 374 
resolution and intra-vitreal therapy may be required.  Due to its efficacy in treating multiple sclerosis 375 
symptoms, fingolimod may become more widely used.  Thus, we suggest that ophthalmic monitoring 376 
of patients should be based upon their visual acuity, OCT findings and co-morbidities, enabling close 377 
monitoring of those at-risk whilst ensuring the burden is manageable. Continued reporting of other 378 
cases in the scientific literature and via the yellow card system should further our knowledge and 379 
experience of this new cause of macular oedema.  380 
 381 
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